- Conditions
- Rectal Cancer
- Interventions
- Epacadostat, Short-course radiation therapy, CAPOX chemotherapy, FOLFOX chemotherapy
- Drug · Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 4
- States / cities
- Orange, California • Boston, Massachusetts • Detroit, Michigan + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–34
of 34
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Colorectal Cancer
- Interventions
- Capecitabine, Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,886 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 48
- States / cities
- Mobile, Alabama • Alhambra, California • Bakersfield, California + 43 more
- Conditions
- Solid Tumor
- Interventions
- 5-FU, Atezolizumab, Bevacizumab, Gemcitabine, Leucovorin, Nab-Paclitaxel, Oxaliplatin, Capecitabine, Cisplatin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 12
- States / cities
- Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 8 more
- Conditions
- Stomach Neoplasms
- Interventions
- Pembrolizumab, Cisplatin, 5-fluorouracil, oxaliplatin, capecitabine, Placebo for Pembrolizumab
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,579 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Orange, California • Miami, Florida + 7 more
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- BBI608, Nab-paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, Fluorouracil, MM-398
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Fort Wayne, Indiana + 9 more
- Conditions
- Pancreatic Cancer
- Interventions
- LY2090314, FOLFOX, Gemcitabine, Nab-paclitaxel
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Colorectal Cancer
- Interventions
- Oxaliplatin 130 mg/m^2, Capecitabine 1000 mg/m^2, Bevacizumab 7.5 mg/kg, Placebo for bevacizumab 7.5 mg/kg, Oxaliplatin 85 mg/m^2, Leucovorin 200 mg/m^2, Fluorouracil 400 mg/m^2, Bevacizumab 5 mg/kg, Placebo for bevacizumab 5 mg/kg
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,035 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 49
- States / cities
- Berkeley, California • Fountain Valley, California • Fullerton, California + 44 more
- Conditions
- Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
- Interventions
- Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT), Capecitabine, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU), Oxaliplatin, Patritumab Deruxtecan
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 5 more
- Conditions
- Advanced Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma
- Interventions
- Zolbetuximab, mFOLFOX6, CAPOX
- Drug
- Lead sponsor
- Midhun Malla
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Gastro-Esophageal Junction Adenocarcinoma, Gastric Cancer
- Interventions
- Nab-paclitaxel 150 mg/m^2, Oxaliplatin 85 mg/m^2, 5-FU 1200 mg/m^2 x 2 D, Leucovorin 400 mg/m^2
- Drug
- Lead sponsor
- Al B. Benson, III, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Lake Forest, Illinois • Iowa City, Iowa + 4 more